PSORIASIS TREATMENT IN ADULTS: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v4i7.3326Keywords:
Psoriasis. Treatment. Adults.Abstract
Psoriasis is a chronic autoimmune skin disease that affects about 2% of the world's population. It is characterized by skin lesions that present inflammation, scaling, and redness. The exact cause of psoriasis is unknown, but it is known that the interaction between genetic, immunological, and environmental factors play an important role in its development. The disease can significantly affect patients' quality of life, affecting physical, emotional, and social aspects. Objective: to describe and dissertate on the main interventional measures focused on the treatment of psoriasis in adults. Results: The search process resulted in a total of 673 findings, after the identification and screening process, 63 studies were selected to discuss the theme. Conclusion: There are different treatment methodologies according to the type of psoriasis and its level between moderate, mild and severe. The main treatments identified were: phototherapy, methotrexate, acitretin, cyclosporine. In addition, within the biologic therapies are: infliximab, etanercepte, adalimumab, certolizumab pegol, ustequinumab, secuquimumab, ixequinumab, guselcumab, risanquizumab, brodalimumab and tildraquizumab.
Downloads
References
ABBVIE. SKYRIZI® risanquizumabe, 2022. Disponível em: https://www.abbvie.com.br/content/dam/abbvie-dotcom/br/documents/Skyrizi-VP.pdf.
ARMSTRONG, April W et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatology, [s. l.], v. 157, n. 8, p. 940–946, 2021. Disponível em: https://doi.org/10.1001/jamadermatol.2021.2007.
ARMSTRONG, April W et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA dermatology, [s. l.], v. 149, n. 10, p. 1180–1185, 2013.
ARNONE, Marcelo et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. Anais brasileiros de dermatologia, Spain, v. 94, n. 2 Suppl 1, p. 76–107, 2019.
ASTRAZENECA. Bula do medicamento Humira® (adalimumabe), 2023. Disponível em: https://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=17596342016&pIdAnexo=2663057.
BARROS, Norami de Moura et al. Fototerapia. Anais Brasileiros de Dermatologia (Portuguese), v. 96, n. 4, p. 397–407, 2021.
BOEHNCKE, Wolf-Henning. Etiology and pathogenesis of psoriasis. Rheumatic Disease Clinics, v. 41, n. 4, p. 665–675, 2015.
BU, Jin et al. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Frontiers in immunology, Switzerland, v. 13, p. 880201, 2022.
COMMITTEE OF PSORIASIS CHINESE MEDICAL ASSOCIATION, Dermatology Branch. Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition#. International Journal of Dermatology and Venereology, [s. l.], v. 3, n. 01, p. 14–26, 2020.
DA COSTA, Jéssica Silva; LAZZARETTI, Camilla. Psoríase: uma revisão dos mecanismos fisiopatológicos da doença. Instituto federal de educação, ciência e tecnologia do Rio Grande Do Sul, p. 66, 2019.
DA SILVA, Flávio Oliveira. Psoríase no couro cabeludo: síntese das principais evidências clínicas. BWS Journal, v. 4, n. 0 SE-Artigos, p. 1–11, 2021. Disponível em: https://bwsjournal.emnuvens.com.br/bwsj/article/view/236.
DA SILVA CASTILHO, Amanda Cristina; LOPES, Camila de Oliveira Pacheco; SALLES, Bruno Cesar Correa. Fisiopatologia da psoríase e seus aspectos imunológicos: uma revisão sistemática. Research, Society and Development, v. 10, n. 11, p. e256101119346–e256101119346, 2021.
DA SILVA, Lívia Ferreira; VEIGA, Wagner Amado. PSORÍASE: ASPECTOS EPIDEMIOLÓGICOS E FISIOPATOLÓGICOS UMA REVISÃO DE LITERATURA. Revista Ibero-Americana de Humanidades, Ciências e Educação, v. 8, n. 9, p. 1241–1257, 2022.
DAGAN, Amir et al. Acute onset of psoriatic spondyloarthritis as a new manifestation of post-streptococcal reactive arthritis: a case series. Clinical Rheumatology, v. 38, p. 2367–2372, 2019.
DAND, Nick et al. Psoriasis and genetics. Acta dermato-venereologica, v. 100, n. 100-year theme: Psoriasis, p. 54–64, 2020.
DE ANDRADE MARCONI, Marina; LAKATOS, Eva Maria. Metodologia do trabalho científico. 2017.
DE CAMARGO, Luiza Helena Angarten Ferraz; VALVASSOURA, Sarah Amancio; RIBEIRO, Maísa. FOTOTERAPIA COM UVBNB E PUVA NO TRATAMENTO DA PSORÍASE MODERADA A GRAVE. Revista Multidisciplinar em Saúde, v. 1, n. 3, p. 16, 2020.
DE OLIVEIRA FRANÇA, Marcely Lorena et al. Caracterização da psoríase e seu tratamento: uma revisão narrativa. SaBios-Revista de Saúde e Biologia, v. 16, p. 1–13, 2021.
DI MEGLIO, Paola; NESTLE, Frank O. Immunopathogenesis of Psoriasis. In: CLINICAL AND BASIC IMMUNODERMATOLOGY. Cham: Springer International Publishing, 2017. p. 373–395. E-book. Disponível em: http://link.springer.com/10.1007/978-3-319-29785-9_21.
DOGRA, Sunil; YADAV, Savita. Psoriasis in India: Prevalence and pattern. Indian Journal of Dermatology, Venereology, and Leprology, v. 76, n. 6, p. 595, 2014. Disponível em: https://ijdvl.com/psoriasis-in-india-prevalence-and-pattern/.
ELI LILLY AND COMPANY. Taltz (Ixekizumab) Injection, for Subcutaneous Use, 2022. Disponível em: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s101lbl.pdf.
FANG, Rouyu; SUN, Qiuning. Guttate Psoriasis. Indian Pediatrics, v. 57, n. 6, p. 596–597, 2020. Disponível em: https://link.springer.com/10.1007/s13312-020-1880-0.
FIORATTI, Cyntia et al. Análise de custo por resposta de adalimumabe, etanercepte, guselcumabe, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe para tratamento de psoríase em placas moderada a grave sob a perspectiva do Sistema de Saúde Suplementar brasileiro. JBES: Brazilian Journal of Health Economics/Jornal Brasileiro de Economia da Saúde, v. 10, n. 3, 2018.
FU, Yun; LEE, Cheng-Han; CHI, Ching-Chi. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA dermatology, v. 154, n. 12, p. 1417–1423, 2018.
GANANANDAN, Kohilan; SACKS, Benjamin; EWING, Iain. Guttate psoriasis secondary to COVID-19. BMJ case reports, [s. l.], v. 13, n. 8, 2020.
GIROLOMONI, Giampiero et al. The role of IL‐23 and the IL‐23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, v. 31, n. 10, p. 1616–1626, 2017.
HEATH, Michael S et al. Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert opinion on drug metabolism & toxicology, , v. 14, n. 9, p. 919–927, 2018.
IZNARDO, Helena; PUIG, Lluís. The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety, v. 19, n. 4, p. 365–372, 2020. Disponível em: https://www.tandfonline.com/doi/full/10.1080/14740338.2020.1730326.
JACQUIMINUT, Camilla Feitosa; AZEVEDO, Geovana Martins; DE LIMA AMAZONAS, Liana. Terapia biológica no tratamento da psoríase moderada a grave: revisão sistemática Biological therapy in the treatment of moderate to severe psoriasis: systematic review. Brazilian Journal of Development, v. 7, n. 11, p. 109388–109401, 2021.
JANSSEN. Stelara® (ustekinumab) for injection, for subcutaneous use, 2022. Disponível em: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125261s107lbl.pdf.
JANSSEN. Tremfya® guselcumabe, 2022. Disponível em: https://www.janssen.com/brasil/sites/www_janssen_com_brazil/files/prod_files/live/tremfya_pub_vps.pdf.
JARIENĖ, Vaiva et al. Psoriasis Inversa in Patient with Hidradenitis Suppurativa: A Case Report. In: , 2022. SPIN 2022-7th Congress of the Skin Inflammation and Psoriasis International Network" Non Stop Improvement. That’s Spin": 6-8 July 2022, Paris, France: abstract book. Paris: Skin Inflammation and Psoriasis International Network, 2022, 2022.
KAWAZOE, S et al. Zur lehre von der neurogenen und der thyreogenen glykosurie (schluss aus no. 18.). Dtsch Med. Wochenschr, v. 23, p. 309–312, 1897.
LIBBS. FAULDMETRO® Bula do metotrexato, 2017. Disponível em: https://www.libbs.com.br/wp-content/uploads/2015/12/Bula-Fauldmetro-Profissional-ampliada.pdf.
LIMA, Emerson de Andrade; LIMA, Mariana de Andrade. Imunopatogênese da psoríase: revisando conceitos. Anais Brasileiros de Dermatologia, [s. l.], v. 86, p. 1151–1158, 2013.
MACHADO, Eleuza Rodrigues et al. Psoríase: uma revisão sistemática da literatura. Revista de Iniciação Científica e Extensão, [s. l.], v. 2, n. Esp. 1, p. 52, 2019.
MARTINS, Heloísa Helena T. Metodologia qualitativa de pesquisa. Educação e pesquisa, [s. l.], v. 30, p. 289–300, 2004.
MCINNES, Iain B et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. New England Journal of Medicine, [s. l.], v. 384, n. 13, p. 1227–1239, 2021.
MENTER, A et al. Guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. Epub, [s. l.], 2019.
MENTER, Alan et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, [s. l.], v. 80, n. 4, p. 1029–1072, 2019. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0190962218330019.
MORAES, Luísa Gouveia Alves et al. Impacto da psoríase em áreas especiais na qualidade de vida e a perspectiva de tratamentos mais promissores: revisão narrativa. Brazilian Journal of Development, [s. l.], v. 7, n. 9, p. 92332–92350, 2021.
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE). Certolizumab pegol for treating moderate to severe plaque psoriasis - Technology appraisal guidance [TA574]. [s. l.], n. April 2019, 2019. Disponível em: https://www.nice.org.uk/guidance/ta574/chapter/1-Recommendations.
NOVARTIS. Cosentyx® (secukinumab) injection, for subcutaneous use, 2023. Disponível em: https://www.cosentyx.com/globalassets/cosentyx/global/en/product-info/cosentyx-prescribing-information.pdf.
OKANE, SERGIO YOSHIMASA; NETO, HÉLIO ANGOTTI. PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS PSORÍASE, 2019. Disponível em: https://www.gov.br/saude/pt-br/assuntos/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt/arquivos/2019/PortariaConjuntan18de14102021_PCDT_Psoriase.pdf.
OKITA, Aline Lissa et al. Tratamento de psoríase vulgar pela microinfusão de medicamentos na pele (MMP®) usando ciclosporina e metotrexato. Surgical & Cosmetic Dermatology, [s. l.], v. 10, n. 1, p. 80–84, 2018.
PAPP, K.A. et al. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, [s. l.], v. 31, n. 8, p. 1324–1332, 2017. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jdv.14313.
PFIZER. Bula do Enbrel. [S. l.: s. n.], 2022. Disponível em: https://www.pfizer.com.br/content/dam/pfizer-brasil/pt_BR/attachments/produtos/Enbrel/bula-enbrel-pfizer-11-02-2020.pdf.
PSORÍASE BRASIL. Relatório global sobre a psoríase. [S. l.]: OMS, Organização Mundial da Saúde, 2017-. ISSN 0029-5582.v. 13 Disponível em: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189-por.pdf?sequence=17&isAllowed=y#:~:text=A psoríase ocorre mundialmente.,e 5%25 (27).
RENDON, Adriana; SCHÄKEL, Knut. Psoriasis pathogenesis and treatment. International journal of molecular sciences, [s. l.], v. 20, n. 6, p. 1475, 2019.
RODRIGUES, José Milton Cordeiro et al. Estresse e psoríase: novas abordagens no tratamento. Revista Eletrônica Acervo Científico, [s. l.], v. 12, p. e4638–e4638, 2020.
RODRIGUES, Karoline Barreto Benevides. OS TRATAMENTOS DA PSORÍASE. BWS Journal, [s. l.], v. 5, p. 1–10, 2022.
RODRÍGUEZ, Génesis Alejandra Cabral; ESTRADA, Christian García; BARRAZA, Erick Elier Blanco. Erythrodermic psoriasis: Case report and literature review. Dermatología Cosmética, Médica y Quirúrgica, [s. l.], v. 20, n. 4, p. 407–411, 2023.
RODRÍGUEZ, Génesis Alejandra Cabral; ESTRADA, Christian García; BARRAZA, Erick Elier Blanco. Psoriasis eritrodérmica: reporte de un caso y revisión de la literatura. Dermatología Cosmética, Médica y Quirúrgica, [s. l.], v. 20, n. 4, p. 407–411, 2023.
ROMITI, Ricardo et al. Psoríase pustulosa generalizada (von Zumbusch). Anais Brasileiros de Dermatologia (Portuguese), [s. l.], v. 97, n. 1, p. 63–74, 2022.
ROMITI, Ricardo; CARVALHO, André Vicente E de; DUARTE, Gleison V. Consenso Brasileiro de Psoríase 2020 e Algoritmo de Tratamento da Sociedade Brasileira de Dermatologia. Anais Brasileiros de Dermatologia, [s. l.], v. 96, n. 6, p. 778–781, 2021.
SBD, Sociedade Brasileira de Dermatologia. Dados da Psoríase. [S. l.], 2022. Disponível em: https://www.sbd.org.br/doencas/psoriase/. Acesso em: 7 mar. 2023.
SINCLAIR, Rodney; THIRTHAR PALANIVELU, Vetrichevvel. Tildrakizumab for the treatment of psoriasis. Expert Review of Clinical Immunology, [s. l.], v. 15, n. 1, p. 5–12, 2019. Disponível em: https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1544493.
SORRENTINO, Andreza Dias Mota. Impacto dos diferentes tipos de dieta na psoríase: uma revisão integrativa de literatura. [s. l.], 2022.
TAKESHITA, Junko et al. Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology, United States, v. 76, n. 3, p. 377–390, 2017.
VASCONCELOS, Henrique Guimarães et al. Psoríase como fator de risco para doenças cardiovasculares: uma revisão da literatura. Brazilian Journal of Development, [s. l.], v. 7, n. 10, p. 99130–99142, 2021.
YAN, Di et al. New frontiers in psoriatic disease research, part I: genetics, environmental triggers, immunology, pathophysiology, and precision medicine. Journal of Investigative Dermatology, [s. l.], v. 141, n. 9, p. 2112–2122, 2021.
ZHOU, Xin; CHEN, Zhuo; BI, Xinling. An update review of biosimilars of adalimumab in psoriasis–Bioequivalence and interchangeability. Drug Design, Development and Therapy, [s. l.], p. 2987–2998, 2021.
ZITO, Patrick M; MAZZONI, Thomas. Acitretin. In: STATPEARLS [INTERNET]. [S. l.]: StatPearls Publishing, 2022.
Downloads
Published
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
